{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-455560","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2026-11-10T21:28:20+00:00","discovered_at":"2026-11-10T21:29:00.282953+00:00","generated_at":"2026-11-10T21:29:06.000033+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Inhibikase Q3 2026 net loss $20.5M; cash $193.3M to fund IMPROVE-PAH through Part B readout","bullets":["Q3 2026 net loss $20.5M ($0.10/share) vs $11.9M ($0.13/share) a year earlier; R&D rose to $15.0M from $7.6M and SG&A to $7.2M from $5.6M.","Cash, cash equivalents and marketable securities were $193.3M at Sept 30, 2026, expected to fund operations through Part B topline, assuming full exercise of Series A and B warrants.","Phase 3 IMPROVE-PAH has 28 country regulatory approvals and 79 of a planned 180 sites activated; Part A interim safety readout (n=50) planned for first half of 2027.","July 2026: sold 25,000,000 shares to RA Capital via ATM for $50M gross; 18,030,000 later exchanged for pre-funded warrants. 140.3M shares and 60.6M pre-funded warrants outstanding.","FDA granted Orphan Drug Designation for IKT-001 in July 2026; board added cardiologist Scott M. Wasserman, MD, CMO of Kailera Therapeutics, in October 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-455560","json":"https://secwatch.observer/filing/0001193125-26-455560.json","markdown":"https://secwatch.observer/filing/0001193125-26-455560.md","text":"https://secwatch.observer/filing/0001193125-26-455560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/0001193125-26-455560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T21:29:06.000033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}